Low-dose aspirin could ‘reduce pancreatic cancer risk’

26 June 2014

The longer a person takes low-dose aspirin, the lower the risk is for developing pancreatic cancer, suggests a new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Dr Harvey A Risch, lead author of the research, said: "We found that the use of low-dose aspirin was associated with cutting the risk of pancreatic cancer in half, with some evidence that the longer low-dose aspirin was used, the lower the risk.

"Because about one in 60 adults will get pancreatic cancer and the five-year survival rate is less than five per cent, it is crucial to find ways to prevent this disease."

There were 362 pancreatic cancer patients and 690 controls were involved in the study. Those who took a low dose of aspirin regularly experienced a 48 per cent reduction in their risk for developing the disease on average.

Protection against this type of cancer ranged from 39 per cent in those who took the medication for six years or less to 60 per cent in those who took it for a decade or more.

Posted by Philip Briggs


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)